Congress keeps SCHIP clean
The House passed reauthorization for the State Children's Health Insurance Program Jan. 14, clearing the bill without any amendments that would affect the pharmaceutical industry. As a bill with strong support, it could have served as a vehicle for tweaking other government health care programs, such as striking the ban on government interference in drug price negotiations for Medicare Part D, but Congress seems content to wait for the broader health care reform debate to take shape
You may also be interested in...
The blockbuster drug is expected to see overall sales declines in the next few years, and biosimilar competition could come as soon as 2023.
Plus deals involving WuXi AppTec/OXGENE, Oscotec/Beatica, ReViral/LianBio, Wugen/HCW Biologics, Starton/Haisco, Shanghai Junshi/AstraZeneca, HitGen/Uppthera, Bridge/LegoChem, Macrogen/Lifex, BeiGene/Boston Immune